Cultural stigmas against treatment may be reduced by providing information about mental health in a second language.

Published Date: 26 Apr 2023

By using interpretation and translation to present information to communities in their native language, public health outreach initiatives frequently aim to break down communication barriers. However, bilingual people from various cultural backgrounds.

Read Full News

Todays Updates


IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA


IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD


Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD


Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What The FDA Psychedelic Hearing Means for Psychiatrists


What The FDA Psychedelic Hearing Means for Psychiatrists

Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab Marco Meglio


A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP Louie Pasculli


A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

Phase 4 Study Shows Stable Motor Function in Adults With SMA on Risdiplam Isabella Ciccone, MPH


Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.

Todays Updates


IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA


IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD


Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD


Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What The FDA Psychedelic Hearing Means for Psychiatrists


What The FDA Psychedelic Hearing Means for Psychiatrists

Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab Marco Meglio


A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP Louie Pasculli


A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

Phase 4 Study Shows Stable Motor Function in Adults With SMA on Risdiplam Isabella Ciccone, MPH


Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Similar survival seen with simple versus radical hysterectomy for cervical cancer

2.

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

3.

There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.

4.

Daily physical activity, even at light intensities, linked to lower cancer risk

5.

PSA Often Unchanged With Enzalutamide Progression


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot